Stage IVB Prostate Cancer AJCC v8

specific

Stage IVB includes: Any T, N0, M1, PSA: Any, Grade Group: Any. N0: Prostate cancer with no positive regional nodes. M1: Prostate cancer with distant metastasis. (AJCC 8th ed.)

80

Centers

305

Active Trials

Cancer Funding

Top Centers for Stage IVB Prostate Cancer AJCC v8(80)

Ranked by research excellence score (trials · grants · publications). Methodology →

#CenterScore
1
High-Volume Research Center
72.8
2
NCI Comprehensive
High-Volume Research Center
72.0
3
High-Volume Research Center
72.0
4
NCI Comprehensive
High-Volume Research Center
71.2
5
NCI Comprehensive
High-Volume Research Center
70.6
669.5
7
NCI Clinical
Active Research Program
69.5
8
NCI Comprehensive
Active Research Program
69.5
9
NCI Comprehensive
Active Research Program
67.8
10
NCI Comprehensive
Active Research Program
67.8
11
NCI Clinical
Active Research Program
67.8
12
NCI Comprehensive
Active Research Program
65.8
13
Active Research Program
65.8
14
Active Research Program
65.8
15
Active Research Program
65.8
16
NCI Comprehensive
Active Research Program
61.6
17
NCI Comprehensive
Active Research Program
61.6
18
NCI Comprehensive
Active Research Program
61.6
19
NCI Comprehensive
Active Research Program
61.6
20
NCI Comprehensive
Active Research Program
61.6
21
NCI Comprehensive
Active Research Program
61.6
22
NCI Comprehensive
Active Research Program
61.6
23
NCI Comprehensive
Active Research Program
61.6
24
Active Research Program
61.6
25
NCI Comprehensive
Active Research Program
61.6
26
Active Research Program
61.6
27
NCI Comprehensive
Active Research Program
55.4
28
NCI Comprehensive
Active Research Program
55.4
29
NCI Comprehensive
Active Research Program
55.4
30
NCI Comprehensive
Active Research Program
55.4
31
NCI Comprehensive
Active Research Program
55.4
32
NCI Comprehensive
Active Research Program
55.4
33
NCI Comprehensive
Active Research Program
55.4
34
Active Research Program
55.4
35
Active Research Program
55.4
36
Active Research Program
55.4
37
Active Research Program
55.4
38
NCI Comprehensive
Active Research Program
48.9
39
NCI Comprehensive
Active Research Program
48.9
40
NCI Comprehensive
Active Research Program
48.9
41
Rutgers Cancer InstituteNew Brunswick, NJ
NCI Comprehensive
Active Research Program
48.9
42
NCI Clinical
Active Research Program
48.9
43
NCI Comprehensive
Active Research Program
48.9
4448.9
45
Active Research Program
48.9
46
Active Research Program
48.9
47
Active Research Program
48.9
48
Active Research Program
48.9
49
Active Research Program
48.9
50
NCI Comprehensive
Active Research Program
40.8
51
NCI Comprehensive
Active Research Program
40.8
52
NCI Comprehensive
Active Research Program
40.8
53
NCI Comprehensive
Active Research Program
40.8
54
NCI Comprehensive
Active Research Program
40.8
55
NCI Comprehensive
Active Research Program
40.8
56
NCI Comprehensive
Active Research Program
40.8
57
Masonic Cancer CenterMinneapolis, MN
NCI Comprehensive
Active Research Program
40.8
58
NCI Comprehensive
Active Research Program
40.8
59
NCI Comprehensive
Active Research Program
40.8
60
NCI Comprehensive
Active Research Program
40.8
61
NCI Comprehensive
Active Research Program
40.8
62
Fox Chase Cancer CenterPhiladelphia, PA
NCI Comprehensive
Active Research Program
40.8
63
Active Research Program
40.8
64
Active Research Program
40.8
65
Active Research Program
40.8
6640.8
67
NCI Comprehensive
Contributing Research Center
32.1
68
NCI Comprehensive
Contributing Research Center
32.1
69
NCI Comprehensive
Contributing Research Center
32.1
70
NCI Comprehensive
Contributing Research Center
32.1
71
NCI Comprehensive
Contributing Research Center
32.1
72
NCI Comprehensive
Contributing Research Center
32.1
73
Cedars-Sinai CancerLos Angeles, CA
Contributing Research Center
32.1
74
Contributing Research Center
32.1
75
NCI Clinical
Contributing Research Center
32.1
76
NCI Comprehensive
Contributing Research Center
32.1
77
NCI Comprehensive
Contributing Research Center
32.1
78
Contributing Research Center
32.1
79
Contributing Research Center
32.1
80
Contributing Research Center
32.1

Research tier badges reflect trial volume, NIH grant funding, and publication impact — not clinical outcomes or patient satisfaction. Learn about our methodology →